Omar Abdel-Wahab MD

Oncology•New York, NY

Hematologic Oncology

Physician

Request appointment

1275 York AvenueNew York, NY 10065
Book by Phone+1(717) 794-7847

Overview of Dr. Abdel-Wahab

Dr. Omar Abdel-Wahab is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Duke University School of Medicine and has been in practice 22 years. Dr. Abdel-Wahab accepts several types of health insurance, listed below. He is one of 537 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
Duke University School of MedicineClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2007 - 2028
NJ State Medical License 2022 - 2027
MA State Medical License 2006 - 2009
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

1 citations
Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias.
Takeshi Fujino, Jennifer Lewis, Bingyi Chen, Tamar Y Feinberg, Maxim I Maron
Cancer Discovery. 2026-10-01
1 citations
Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis.
Alicia G Aguilar-Navarro, Gibran Edun, Mark Gower, Joan Kant, Ximing Li
Nature Immunology. 2026-09-30
The cellular landscape of druggable RNA-binding proteins.
Gaia Di Timoteo, Benson M George, Omar Abdel-Wahab, Ryan A Flynn, Konstantinos Tzelepis
Nature Reviews. Drug Discovery. 2026-09-29

Abstracts/Posters

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias
Omar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias
Omar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
Omar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Neoantigen-Based T-cell Receptor Therapy Offers New Option for Patients with AML, MDSMay 6th, 2025
A New Cellular Immunotherapy Approach May Offer Treatment for AML and MDSApril 23rd, 2025
FDA Approves First Treatment for Patients with All Forms of HistiocytosisJanuary 30th, 2023

Grant Support

Understanding and Targeting Aberrant RNA Splicing in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2025–2032
The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2031
Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemiaSLOAN-KETTERING INST CAN RESEARCH2025–2030
MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2030
Genetic and molecular basis for SRSF2 mutations in myelodysplasiaFRED HUTCHINSON CANCER CENTER2015–2029

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
First Health PPO
GHI PPO
Great West PPO
Health Net Oregon PPO
HealthAmerica HealthAssurance PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
Regence Washington - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment